Pharmacology Research Today is a free monthly online journal that collates and summarizes the latest research about Pharmacology, including details on pharmacogenomics, drug development, new medications.

Volume 5 (2009), Issue 11 (November)

1. Using cells devoid of RAS proteins as tools for drug discovery.
   Mol Carcinog, 48(11): 1038-47. [Abstract] [Full-text]
2. Target gene discovery for novel therapeutic agents in cancer treatment.
   Methods Mol Biol, 576: 427-45. [Abstract] [Full-text]
3. Identification of intermediates and assessment of ecotoxicity in the oxidation products generated during the ozonation of clofibric acid.
   J Hazard Mater, 172(2): 1061-8. [Abstract] [Full-text]
4. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment.
   J Natl Cancer Inst, 101(21): 1453-63. [Abstract] [Full-text]
5. In silico toxicology for the pharmaceutical sciences.
   Toxicol Appl Pharmacol, 241(3): 356-70. [Abstract] [Full-text]
6. Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies.
   Toxicol Lett, 191(1): 88-95. [Abstract] [Full-text]
7. Phylogeny and primary structure analysis of fiber shafts of all human adenovirus types for rational design of adenoviral gene-therapy vectors.
   J Gen Virol, 90: 2849-54. [Abstract] [Full-text]
8. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard.
   Stat Med, 28(27): 3437-53. [Abstract] [Full-text]
9. Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology.
   Clin Pharmacol Ther, 86(6): 678-82. [Abstract] [Full-text]
10. Forecasting risk along a river basin using a probabilistic and deterministic model for environmental risk assessment of effluents through ecotoxicological evaluation and GIS.
    Sci Total Environ, 408(2): 294-303. [Abstract] [Full-text]
11. Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors.
    J Med Chem, 52(22): 7289-300. [Abstract] [Full-text]
12. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse.
    J Med Chem, 52(22): 7301-9. [Abstract] [Full-text]
13. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    J Med Chem, 52(22): 7132-41. [Abstract] [Full-text]
14. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
    J Med Chem, 52(22): 7170-85. [Abstract] [Full-text]
15. Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement.
    J Med Chem, 52(22): 7069-80. [Abstract] [Full-text]
16. Novel compounds designed as antistress agents.
    J Med Chem, 52(22): 7315-8. [Abstract] [Full-text]
17. From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.
    J Med Chem, 52(22): 6966-78. [Abstract] [Full-text]
18. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
    J Med Chem, 52(22): 7044-53. [Abstract] [Full-text]
19. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    J Med Chem, 52(22): 7081-9. [Abstract] [Full-text]
20. Rational drug design.
    Eur J Pharmacol, 625(1): 90-100. [Abstract] [Full-text]
21. Drug development for orphan diseases in the context of personalized medicine.
    Transl Res, 154(6): 314-22. [Abstract] [Full-text]
22. Pharmacogenetic profiling in the treatment of heart disease.
    Transl Res, 154(6): 295-302. [Abstract] [Full-text]
23. The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum--new tools for designing specific inhibitors.
    Biochem Biophys Res Commun, 390(3): 963-70. [Abstract] [Full-text]
24. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.
    Biochem Pharmacol, 79(3): 330-8. [Abstract] [Full-text]
25. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    J Pharmacol Exp Ther, 331(3): 767-74. [Abstract] [Full-text]
26. Mutational and inhibitory analysis of a catalytic antibody. Implication for drug discovery.
    Mol Immunol, 47(2): 348-56. [Abstract] [Full-text]
27. Predictive computational models of substrate binding by a nucleoside transporter.
    J Biol Chem, 284(49): 34028-35. [Abstract] [Full-text]
28. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
    Mol Immunol, 47(2): 332-9. [Abstract] [Full-text]

© 2005-2013 Pharmacology Research Today. All Rights Reserved.